|Articles|September 22, 2016

EpiPen Controversy: Mylan CEO Faces Congressional Committee

September 22, 2016

Mylan CEO Heather Bresch appeared before the House Committee on Oversight and Government Reform on Sept. 21, 2016 to explain the company’s decision to increase the price of EpiPen more than 400%. The meeting comes after multiple members of Congress raised concerns about the price of the life-saving drug, which is used to treat anaphylaxis.

In her pre-released testimony, Bresch attempted to clarify exactly how much money Mylan makes off each EpiPen sale.

For the rest of this news release, see Pharmaceutical Technology.

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

EpiPen Controversy: Mylan CEO Faces Congressional Committee

Related Content

Utilizing 100-Percent Domestic Additive Manufacturing: Q&A with Kyle Smith

Insilico Announces Collaboration with SK Biopharmaceutical for AI-Powered CNS Treatment

Additive Manufacturing's Application in Pharma and Biotech

Expanding the Vaccine Landscape with New Technologies: Q&A with Silvia Taylor

The ROI of Smarter Trials: Q&A with Raj Indupuri

Trending on PharmExec

FDA Clears Trodelvy for First-Line Metastatic Triple-Negative Breast Cancer

The Rise of Direct-to-Patient Models in Pharma: Opportunities and Risks in Bypassing Traditional Distribution Channels

Novartis Announces $105 Million Collaborative Agreement with Antares Therapeutics

The Economics of the 340B Drug Pricing Program: Strategic Imperatives for the Life Sciences Industry in 2026

Pharmaceutical Executive Daily: Eli Lilly and Abbisko Announce Drug Development Collaboration